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Diagnosis of genital herpes simplex virus
infection in the clinical laboratory
Jérôme LeGoff1*, Hélène Péré2,3 and Laurent Bélec2,3
Abstract
Since the type of herpes simplex virus (HSV) infection affects prognosis and subsequent counseling, type-specific
testing to distinguish HSV-1 from HSV-2 is always recommended. Although PCR has been the diagnostic standard
method for HSV infections of the central nervous system, until now viral culture has been the test of choice for
HSV genital infection. However, HSV PCR, with its consistently and substantially higher rate of HSV detection, could
replace viral culture as the gold standard for the diagnosis of genital herpes in people with active mucocutaneous
lesions, regardless of anatomic location or viral type. Alternatively, antigen detection—an immunofluorescence
test or enzyme immunoassay from samples from symptomatic patients–could be employed, but HSV type
determination is of importance. Type-specific serology based on glycoprotein G should be used for detecting
asymptomatic individuals but widespread screening for HSV antibodies is not recommended. In conclusion, rapid
and accurate laboratory diagnosis of HSV is now become a necessity, given the difficulty in making the clinical
diagnosis of HSV, the growing worldwide prevalence of genital herpes and the availability of effective antiviral
therapy.
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Introduction
Key structure elements for diagnosis
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)
are large double-stranded DNA viruses of the Herpeto-
viridae family, alphaherpetovirinae sub-family [1]. HSV-1
and HSV-2 share a similar genome structure, with 40%
of sequence homologies reaching 83% homology of their
protein-coding regions, explaining numerous biological
similarities and antigenic cross-reactivity between the
two types. HSV-1 and HSV-2 genomes each encode at
least 80 different structural and non-structural polypep-
tides including at least 10 different viral glycoproteins of
which most are embedded in the viral envelope (gB, gC,
gD, gE, gG,gH, gI, gL, gM, gN) [1]. The majority of the
antibody response to HSV infection is raised against
these surface glycoproteins. Glycoprotein gB, gC, gD and
gE trigger potent immune responses. Some epitopes
present on these glycoproteins are shared by HSV-1 and
HSV-2, and are causing a significant degree of cross
reactivity. However, no cross reactivity between glyco-
protein gG1 in HSV-1 and gG2 in HSV-2 can be de-
tected [2] which is why antibodies to this glycoprotein
are used for type-discriminating serology. While the type
common gB and gD display high similarity (85%) the
homology betweengG-1 and gG-2 is much lower, pre-
senting an overall amino acids (aa) identity of <30%. The
reason for this is that gG-1 of HSV-1 contains 238 aa,
while gG-2 of HSV-2 comprises 699 aa [2]. Furthermore,
the envelope glycoprotein G (gG-2) of HSV-2 is cleaved
into a membrane-bound portion (mgG-2) and a secreted
portion (sgG-2). However, the epitopes for the type-
specific antibodies against mgG-2 are not located in the
portion of mgG-2 which is lacking in gG-1 but in a re-
gion with aa similarity to gG-1. This sequence, located
between aa 560 and 573 for HSV-2 gG and between aa
80 and 93 for HSV-1 gG, carries nine identical residues
between gG-1 and mgG-2 and five type-specific residues
that induce significant structural differences. This results
in different exposure of key residues utilized for recogni-
tion and explains the lack of cross-reactivity [3].
Other similarities and differences between the genomes
of HSV-1 and HSV-2 are used also for genera- or type-
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specific molecular assays, including genes coding for some
envelope glycoproteins or the DNA polymerase. The con-
served gene coding for DNA polymerase is often used for
the detection or quantitation of both types and based on a
few mismatches between HSV-1 and HSV-2 sequences
which may also be used for typing [4,5].
Burden of genital herpes
HSV-1 and HSV-2 are ubiquitous, affecting both urban and
remote populations worldwide [6]. HSV-1 seroprevalence
reaches 50 to 70% in developed countries and 100% in de-
veloping countries and HSV-2 seroprevalence varies from
10 to 40% and may reach 6095% in HIV-infected individ-
uals and female sex workers.
The classical pattern of HSV-1 and HSV-2 infections as-
sociated with oral or genital diseases, respectively, remains
the rule in certain parts of the world such as sub-Saharan
Africa where HSV-1 infection remains a mandatory com-
munity acquired disease in childhood, and HSV-2 infection
a sexually transmitted infection (STI) in adults. In contrast,
the differentiation of HSV-1 from HSV-2 based on anatom-
ical site of infection is far from absolute in developed
countries, the proportion of genital ulcers associated
with HSV-1 infection has become predominant in some
developed countries [6,7]. This is the result of both the
delay in acquisition of oral HSV-1 infection early in life in
developed countries (rendering a significant proportion of
young adults always susceptible to genital HSV-1 infection
at initiation of sexual activity) and the oro-genital sexual
practices. This feature is concerning in regards to neonatal
herpes given that the risk of HSV vertical transmission is
higher during primary infection than during reactivation
[8] and that HSV-1 appears more readily transmissible to
the neonate than HSV-2 [9]. It should be noted that geni-
tal HSV-1 infection does not prevent any risks of genital
HSV-2 acquisition [9].
Worldwide, HSV-2 remains the main cause of genital
herpes and is the major etiology of genital ulcer disease. In
addition, HSV-2 infection has been proven to be an inde-
pendent cofactor of HIV sexual transmission. In turn HIV-
1 infection increases the frequency of HSV-2 reactivations
and mucosal shedding, as well as the quantity of shed vi-
ruses [7]. In severely immunocompromised HIV-1-infected
patients and transplant patients, HSV infections frequently
present as chronic, necrotic, extended, and confluent mu-
cocutaneous ulcerations.
Most primary genital infections with HSV-1 and HSV-
2 are asymptomatic and all are followed by latent infec-
tion of neuronal cells in the dorsal root ganglia and only
1025% of people with HSV-2 antibodies are aware of
their genital herpes. However, a large proportion of sero-
positive patients present asymptomatic shedding epi-
sodes that contribute to the spread of these infections
[10,11].
Importance of laboratory diagnosis or testing for genital
herpes
Genital herpetic infection is mainly diagnosed on clinical
grounds, especially when the clinical picture is classical,
with the presence of typical papular lesions progressing to
vesicle and ulcerative lesions which finally crust, associated
with local adenitis and in recurrent cases preceded by pro-
dromal [12] (Figure 1). However, clinical diagnosis of geni-
tal herpes may be limited in accuracy. The clinical
differentiation of genital HSV infection from other infec-
tious (Treponemapallidum, Haemphilusducreyi) and non-
infectious etiologies of genital ulceration is often difficult
and laboratory confirmation of the infection should always
be sought [13]. Besides classic vesicular lesions, HSV genital
infection may be associated with other clinically atypical
presentations. These include either unusual sites (extrageni-
tal regions: buttocks, thighs) or atypical morphological
forms of genital disease (vulvar, penile or perianal fissures,
localized recurrent erythema, recurrent radicular or lower
back pain, cystitis, urethritis, vaginal discharge without
overt genital lesions) [14,15]. Meningitis may be observed
during phases of primary infection and reactivation and can
also confuse the diagnosis of genital HSV infection [16].
Accordingly, exclusive reliance on clinical diagnosis could
lead both to false positive and false negative diagnosis of
the condition. Thus, a clinical diagnosis of genital herpes
should be confirmed with laboratory tests [6,12,17-19].
The laboratory diagnosis of genital herpes is recom-
mended in various situations:
 Confirmation of clinically suspected genital herpes.
 Variable presentation of genital herpes.
 Extra-genital complications of genital herpes [20].
 Differential diagnosis with other ulcerative STIs.
 Differential diagnosis with other genital ulcerative
dermatoses (Crohn’s disease, Behçet syndrome or
fixed drug eruption).
Because HSV-1 has become a frequent etiology of genital
herpes, species typing is also a cornerstone of genital herpes
diagnosis. Whether genital herpes is caused by HSV-1 or
HSV-2 influences prognosis and counseling. Even though
up to 50% of first-episode cases of genital herpes are caused
by HSV-1, recurrences and subclinical viral shedding are
much less frequent for genital HSV-1 infection than genital
HSV-2 infection. Thus, information regarding whether one
is infected with HSV-1 or HSV-2 can prove useful in dis-
cussing risks for recurrence.
Laboratory methods for direct herpes diagnosis
Collection, transport and storage of clinical specimens for
herpes diagnosis
HSV-1 and HSV-2 can be recovered by swabbing muco-
cutaneous genital lesions and from previously involved
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mucocutaneous sites in patients with asymptomatic
infection.
For sample lesions collection, a small cotton, cotton-
tipped, or Dacron swab on a wire shaft is used for viral
culture as well as molecular biology. Nylon flocked
swabs may be preferred since their perpendicular nylon
fibers act like a soft brush to allow the improved collec-
tion and release from patient samples although no for-
mal validation for herpes positive samples has been
performed yet [21-23]. Calcium alginate swabs are toxic
to HSV and therefore should not be used for virus isola-
tion in cell culture [24].
For active lesions, collection of vesicular fluid or exud-
ate from small vesicles is the method of choice. After
sampling, the specimens for viral culture, antigen or de-
tection of HSV DNA genome should be placed immedi-
ately into vials containing 1 ml of appropriate viral
transport medium, or an universal transport medium be-
cause HSV is highly sensitive to desiccation and pH in-
activation. Specimen should also be transferred quickly
to a diagnostic virology laboratory on ice (+4°C) as the
virus infectivity is heat labile. Molecular assays that do
not require the virus infectiousness, tolerate less strict
conditions for the sample transport. The use of transport
medium may be not necessary as long as samples are
stored at +4°C and frozen until molecular analysis. It has
been shown that inappropriate storage decreased the
yield of HSV DNA [25].The level of viral nucleic acids
collected from cervicovaginal lavages remain stable at
4°C for 24 hours but decreased significantly when they
were stored at 20°C and 30°C [25].
For a diagnosis using cell culture, the use of alcohol or
iodophors to cleanse the lesions before sampling the le-
sion should be avoided as it inactivates the virus.
The recommended sampling sites and type of sample
and methods to be used for the diagnosis of genital
herpes infection are presented in Table 1. The recom-
mendations for sample transportation and storage using
microscopy, culture and nucleic acid amplifications tests
(NAAT) are presented in Table 2.
Laboratory methods for direct herpes diagnosis
Several tests with various specificities and sensitivities
are used for the direct diagnosis of HSV infections
(Table 3).
Viral culture with further herpes typing has been the
cornerstone of HSV diagnosis over the past two decades
and accepted as the gold standard for the laboratory
diagnosis of HSV infections.
Viral antigen can be easily detected by direct immuno-
fluorescence (IF) assay using fluorescein-labelled type-
specific monoclonal antibodies on smears, or by enzyme
immunoassay (EIA) on swabs. Although these assays lack
sensitivity, they perform satisfactorily in symptomatic pa-
tients. Thus, these direct methods may offer a rapid diag-
nostic alternative in settings where laboratory facilities are
limited, including resources-constrained countries.
Recently, HSV DNA detection based on nucleic acid
amplification, and polymerase chain reaction (PCR) in par-
ticular, has emerged as an alternative method because it is
about four times more sensitive, less dependent on collec-
tion and transport conditions, and faster than viral culture
[26]. The 2010 CDC Sexually Transmitted Diseases Treat-
ment Guidelines state that PCR testing to diagnose herpes
can be performed by clinical laboratories that have devel-
oped their own tests and have conducted a Clinical Labora-
tory Improvement Amendment (CLIA) verification study,
and cell culture and PCR are the preferred HSV tests for
people who seek medical treatment for genital ulcers or
other mucocutaneous lesions (CDC, 2010). Since 2011
three molecular assays have been approved by the US Food
and Drug Administration for the testing of genital
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Figure 1 Clinical course of primary genital herpes.
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specimens (IsoAmp HSV Assay, BioHelix Corporation;
MultiCode-RTx Herpes Simplex Virus 1 & 2 Kit, EraGen
Biosciences, Inc.; BD ProbeTec Herpes Simplex Viruses
(HSV I & 2) QX Amplified DNA Assays, BD Diagnostic
Systems).
Based on our practice, when molecular testing is avail-
able, its use should be preferred over viral culture. Mo-
lecular testing will also confirm viral shedding whether
or not lesions are present [27]. When no facilities are
available to carry out cell culture or molecular assays,
Table 1 Recommendations for sample collection for the diagnosis of genital herpes infections, adapted from Domeika
and colleagues [9]
Collection site Tools for sample collection Collection method
Male skin or mucous
membrane lesions
• Sterile needles • Unroof the vesicles with a sterile needle
• Sterile cotton-tipped, Dacron or nylon flocked
swab on a wooden, plastic or aluminium shaft
• Collect the content of the vesicles with a sterile swab and:
○ apply to a microscope slide (for immunofluorescence staining) or ○
introduce into transport media for viral culture or NAAT.• Microscope slides
Male urethra • Sterile cotton-wool, Dacron or nylon flocked
swab on a wooden, plastic or aluminium shaft
• Clean the external urethral opening region with a swab moistened in
saline
• Draw back the prepuce to avoid contamination when sampling
• Insert a sterile swab carefully into the external urethral meatus (to a
depth of 0.5–2 cm) and collect urethral exudates for testing
Female skin or
mucous membrane
lesions
• Gauze and cotton swabs,, dacron or nylon
flocked swab on a wooden, plastic or
aluminium shaft
• Similarly as for male skin or mucous membrane lesions
• Microscope slides
Female urethra • Sterile gauze swab (to remove excess
discharge)
• Clean the introitus using a sterile gauze swab
• Sterile cotton-wool, Dacron or nylon flocked
swab on an aluminium shaft
• Carefully insert a sterile swab on an aluminium shaft into the urethra (to
a depth of 0.5 cm) to collect exudates for testing
Cervix • Vaginal speculum • Insert the vaginal speculum, which may be moistened in advance with
warm water and
• Sterile gauze swab
• Sterile cotton-wool, Dacron or nylon flocked
swab on a wooden or plastic shaft
• clean the cervical canal opening thoroughly with a sterile gauze swab
• Insert a cotton-wool or Dacron swab carefully into the cervical canal (to
a depth of 2 cm) and collect the material from lesions.
Vagina(of
prepubertal girls)
• Sterile cotton-wool, Dacron or nylon flocked
swab on an aluminium shaft
• Insert a sterile swab on an aluminium shaft carefully through the hymen
into the vagina, and collect the material from the back wall of the
vagina
Urine • Sterile container for urine • Ask the patient to collect the first 10–20 ml of voided urine (first catch)
• The patients should avoid urinating for least two hours before sampling
Conjunctiva • Sterile cotton-wool, Dacron or nylon flocked
swab on an aluminium shaft
• purulent discharge must be removed before sampling with a sterile
swab
• Kimura platinum conjunctival scraper • Move a swab over the conjunctiva of the inferior eyelid towards the
interior angle of the eye (use a thin swab on an aluminium shaft for
newborns)
• Topical ophthalmic local anaesthetic
• The Kimura scraper is used to sample the bases of lesions (either ulcers
or the bases of burst vesicles). Before collecting the sample, the spatula
is sterilised by heating in a flame and allowed to cool
Rectuma • Rectal speculum or proctoscope • Rectal material is taken under direct vision, with the aid of a proctoscope
or rectal speculum. Use of a blind technique results in considerable loss
of sensitivity
• Sterile cotton-wool, Dacron or nylon flocked
swab on a wooden or aluminium shaft
• Insert a swab on a wooden or plastic shaft to a depth of 3 cm and
collect the material from all rectal walls by circular motions for
10 seconds
• If faecal material is impacted, the swab should be discarded and the
sampling procedure repeated.
aMaterial from the rectum is collected when the patient has had anal sexual contact, when he suffers from anorectal inflammation, or if perianal skin or anal folds
are thickened.
NAAT: nucleic acid amplification test.
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antigen detection is useful and can provide a rapid diag-
nosis, mainly when mucocutaneous lesions are present.
The recommended sites and methods to be used in
the direct diagnosis of genital herpes lesions are pre-
sented in Table 4.
Virus isolation and typing in cell culture
Several primary, diploid and continuous cell lines may
be used for isolation of HSV from clinical specimens.
Commonly used cells, sensitive to different viruses, in-
clude mainly primary human diploid fibroblasts, such as
MRC-5 cells, and cell lines, such as Vero cells (monkey
kidney), HEp-2 cells (laryngeal squamous cell carcin-
oma), baby hamster kidney and rabbit kidney cells [28].
The parallel inoculation of two different cell lines can
minimize the effects of periodic variations in cell line
sensitivity.
Culture cells are first allowed to grow into a confluent
monolayer in a tissue culture tube flattened on one side.
The cytopathic effect (CPE) caused by HSVusually develops
24-72 hours after inoculation, and is characterized by en-
larged, refractile, and rounded cells. Focal necrosis of cells
may occur and syncytia and multinucleated giant cells may
be present. Within days, the monolayer may be destroyed.
The incubation time required to observe the cytopathic ef-
fect of HSV depends on the concentration of the virus in
the clinical specimen: samples with high titers of virus pro-
duce CPE in less than 48 hours, whereas samples with a
low concentration produce CPE after 4-6 days. Cultures
should be held for seven to 10 days. The highest isolation
rates of HSV are likely if the clinical specimens are inocu-
lated on the day they are taken. It is important to give at-
tention to the conditions of transport and storage of
clinical specimens. They must be stored at +4°C during
transport and maintained at this temperature for no longer
than 48 hours. At ambient temperature, transport duration
should be less than 4 hours. If a delay of more than 48 hours
is expected between collection and culture, the specimens
should be frozen at best at -80°C for further inoculation.
Virus titers are remarkably reduced in frozen and thawed
samples, and freezing at -20°C is not advised [25].
Confirmation of HSV in viral culture demonstrating
cytopathic effect is recommended since other viruses
may exhibit a cytopathic effect similar to that observed
Table 2 Recommendations for sample transportation accordin g to the test method, adapted from Domeika and
colleagues [9]
Test method Conditions Comments
Viral culture • Immediately after sampling the material must be placed in
appropriate transport medium, such as Eagle’s medium with
addition of antibiotics
• Herpes simplex virus is sensitive to both the
temperature and to drying out
• The material should preferably be transported to the laboratory
on ice, and kept at °4°C for up to 48 hours
• Material should not be kept for more than 4 hours at room
temperature
• Accurately marked test tubes must be placed in a hermetic
reservoir and transported to the laboratory accompanied by the
relevant documentation including the investigation method
requested
Antigen detection and
nucleic acid
amplification tests
Transport medium is usually provided by the manufacturer of the
diagnostic commercial assay
• The material is generallly delivered in special test
tubes with transport medium according to the
manufacturer’s instructions for each test
• If the sample transportation procedure is not described in the
manufacturer’s instructions or in-house test systems are used,
transportation is performed as follows:
o Clinical material placed in univesal transport medium should be
transported in a cool bag at 4 ± 2°C
o Urine should be delivered to the laboratory within three hours
of collection, at ambient temperature
• Test tubes containing clinical material should be transported to
the laboratory accompanied by the relevant documentation
including the investigation method requested
Microscopy (direct
examination or
immunofluorescence)
• If there is a need to save the material for more than 24 hours,
the smear should be fixed with 96% ethyl alcohol for three
minutes
• If the rules of sampling and conditions of
transportation of the biological material are not
followed (e.g. slides are broken, unmarked or stuck
together or there is no material on the slide),
microscopy examination should not be carried
out
• Each smear on a microscope slide should be placed in the
transportation container and transported to the laboratory
accompanied by the relevant documentation including the
investigation method requested • Method rarely used now
NAAT: nucleic acid amplification test.
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Table 3 Direct laboratory methods for HSV diagnosis
Method Principle Sample Sensitivity Specificity Advantages Disadvantages
Viral antigen
detection
Immunopreoxidase staining Swab Middle (80%) High (90%) Reagent cost Fresh vesicles
Smears from lesions Rapid (<4 hours
possible)
Suboptimal sensitivity
Smear or vesicular
fluid of exudate from
base of vesicle
Does no require
the integrity of the
specimen
Typing possible
Capture ELISA Swab High (Genital
ulcer: >95%)
High (62-100%) Fresh vesicles
Vesicular fluid or
exudate from base of
vesicle
No viral typing
Rapid test device Swab Unknown Unknown Point-of-care
testing
Not yet evaluated
Vesicular fluid or
exudate from base of
vesicle
Virus culture HSV isolation susceptible cells Swab Low to high
depending of the
clinical context
High (≈100%) Allows virus
isolation
Less sensitive than PCR
Skin lesions Sample storage and transport conditions
influence sensitivityClassically, “gold
standard” methodVesicular fluid or
exudate from base of
vesicle
Vesicular content :
>90%
(➜ Rapid transport, cooled, protected from
light in virus transport medium)Currently,
“preferred” test
(CDC 2010)
Ulcer : 95%
Swab : 70%-80% Labor-intensive
Mucosal sample
without lesions
Biopsies
Mucosa without
lesion: 30%
Simplicity of
sampling
Expensive
Virus typing Specialized laboratories
Resistance Results in 2/7 days
Phenotype testing* Arrangement with laboratory necessaryConjunctival/corneal
smear
Neonates
Molecular
biology
HSV DNA detection and/or quantitation by
NAAT, including in-house classical PCR, real-
time PCR and commercial assays
Swab Highest High. High sensitivity. Only in specialized laboratories
Skin lesions (98%) (≈100%)
Vesicular fluid or
exudate from base of
vesicle
Containment of
potential cross-
contamination
important
Currently,
“preferred” test
(CDC 2010)
Not standardized
Allows virus
detection and
typing in the same
test
Not validated for all samplesMucosal sample
without lesions
Risk of contamination (PCR)
May be relatively expensive (real-time PCR)
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Table 3 Direct laboratory methods for HSV diagnosis (Continued)
Rapid
Aqueous/vitreous
humor
May be automated.
Labor efficient Routine resistance genotyping not available
Cortico-spinal fluid
Result within 24–
48 h, possibly in
<3 hours
Blood
Resistance
genotyping
Method of choice
for CSF
Real-time PCR:
Rapid amplification
Quantitative
analysis
Reduced risk of
contamination
Method of choice
for skin lesions
Cytological
examination
Tzanck smears Skin/mucosal lesions Low Low Inexpensive Fresh lesions
Papanicolaou or Romanovsky stain low sensitivity and no distinction between
HSV-1 and HSV-2, nor between HSV and
varicella zoster virus infection
Biopsies
Conjunctival/corneal
smears
Detection of infected cells by direct
immunoflorescence
Smears, Tissue
section Smear from
base of vesicle
Middle High Inexpensive Fresh vesicles
(Genital ulcer: 70-
90%
(>95%) Rapid (<4 hours
possible)
Suboptimal sensitivity
Asymptomatic : <
40-50%)
Typing possible Time-consuming
Labor-intensive
Not standardized
*The detection of resistance mutations to anti-herpetic drugs (aciclovir) by HSV drug resistance genotyping is likely to supplant phenotypic testing in the next few years.
NAAT: nucleic acid amplification test; CDC : Centers for Disease Control.
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in herpes culture, and allows viral typing. Typing of
HSV using cell culture can be performed directly on
infected cell cultures using fluorescein-labelled type-
specific monoclonal antibodies by direct immunofluores-
cence which constitutes the most practicable procedure,
or, eventually, by testing the cell supernatant by molecular
assays [28].
As standard virus isolation in tissue culture may be
slow, in particular for samples with low viral titers,
many laboratories now use centrifugation-enhanced
(shell vial) culture methods combined with staining
with a type-specific monoclonal antibody before the
CPE onset to reduce viral isolation times [29,30]. Shell
vial culture can reduce viral isolation time from one to
seven days to just 16-48 hours.
Genetically engineered cell lines have been developed
to allow an early detection of HSV-1 and HSV-2 after
an overnight incubation. The Enzyme Linked Virus In-
ducible System (ELVIS, Diagnostic Hybrids, Inc, USA)
utilizes genetically engineered cell lines transfected with
an inducible HSV promoter gene linked to anEscheri-
chia coliLacZ reporter gene [31]. Replication of HSV in
these cells induces galactosidase production, and in-
fected cells stain blue when overlaid with an appropri-
ate substrate [32]. Typing can then be performed using
type-specific antisera on any monolayers showing blue
cells.
Diagnosis of HSV infection with tissue culture has
low sensitivity because HSV is isolated from lesions in
about 80% of primary infections but in only 2550% of
recurrent lesions, and in even fewer people whose le-
sions have begun to heal. Thus, fluid collected from in-
tact blisters (vesicular or pustular lesions) will grow out
in culture more than 90% of the time. By the time the
lesions have crusted over, only about 25% of cultures
will be positive. Failure to detect HSV by culture does
not indicate an absence of HSV infection [26].
Antigen detection
Viral antigen can be easily detected by direct or indirect
immunofluorescence (IF) assay using fluorescein-labelled
type-specific monoclonal antibodies on smears, or by en-
zyme immunoassay (EIA) on swabs. For detecting HSV in
lesions, the sensitivity of antigen detection tests may be the
same as that of culture assay but is lower than nucleic acid
amplification test sensibility [4]. As indirect IF assay and
EIA perform satisfactorily in symptomatic patients, these
direct methods may offer a rapid diagnostic alternative in
settings where laboratory facilities are limited and where
specimen handling and transportation conditions could in-
activate the virus. This is true for remote locations where
prolonged specimen transport time under inappropriate
conditions may occur before delivery to the microbiology
laboratory.
For immunofluorescent assays, the slide should be pre-
pared by the laboratory using a cytospin method to
guarantee the quality of the slide reading. Under a fluor-
escence microscope, infected cells will be recognized by
the presence of a characteristic pattern of apple-green
fluorescence in the nucleus and cytoplasm of the basal
and parabasal cells.
Several EIA assays are commercially available but few
have been FDA approved.
Virus detection and quantification by molecular biology
Molecular biology has emerged for the last ten years as
an attractive potent method to detect and possibly quan-
tify HSV DNA. Most of NAATs are based on the PCR
but some use a different approach for the amplification
of nucleic acid.
Several procedures have been proposed to detect and/
or quantify HSV genomes in clinical samples, including
in-house competitive PCR [33], PCR detection followed
by DNA enzyme immunoassay hybridization [34], real-
time PCR assay [4,5,35,36], and various commercially
available kits. The majority of in-house or commercial
PCR targeting the HSV genome are currently based on
real-time PCR which allows both the detection and the
quantification of HSV DNA in clinical samples. Com-
pared with traditional PCR (also called end-point PCR)
revealed either with agarose gel migration or enzyme
hybridization assay, real-time PCR is faster, less labor-
intensive with minimal technical hands-on time and a
lower risk of molecular contamination. Primers from
HSV DNA sequence common to both HSV-1 and HSV-
2 [HSV DNA polymerase, HSV thymidine kinase or
glycoprotein B] may identify HSV DNA. In some assays,
a melting curve at the end of real-time PCR helps dis-
cern HSV-1 from HSV-2 [4,5,36]. Primers and probes
from HSV DNA sequence specific to HSV-1 or HSV-2,
including, gB, gD, or gG genes, allows also the amplifica-
tion of one specific herpes type [35,37-40]. In each
Table 4 Recommended sampling sites, type of sample
and preferred diagnostic methods for genital herpes,
adapted from Domeika and colleagues [9]
Sampling site or type of sample Preferred diagnostic method
Vesicule on skin and mucous
membranes Ulcer
NAAT; viral culture;
antigen detection*
Urethra (male) NAAT; antigen detection*
Cervix/urethra (female) NAAT; antigen detection*
Urine (men and women) NAAT; viral culture
Vulva/vagina (prepubertal girls) NAAT
Vagina (women after hysterectomy)
*Viral antigen detection by direct immunofluorescence on smears or enzyme
immunoassay on swabs may offer a rapid diagnostic alternative in settings
where culture or molecular diagnosis are not available.
NAAT: nucleic acid amplification test.
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experiment positive and negative controls should be run.
In addition, the use of internal controls spiked before
nucleic acid extraction is recommended to detect the
presence of any amplification inhibitors that could lead
to false-negative results.
PCR assays or other NAATs are the most sensitive test
currently available to detect HSV in clinical samples.
The detection rates of the PCR assays were shown to be
1171% superior to virus culture [26,41-44]. Further-
more, NAAT allows the best detection of asymptomatic
shedding of genital herpes beside symptomatic infections
[26]. However, failure to detect HSV by PCR does not
indicate an absence of HSV infection, because viral
shedding is intermittent [11].
Three NAATs have been approved by the US Food and
Drug Administration for the testing of genital specimens
(IsoAmp HSV Assay, BioHelix Corporation; MultiCode-
RTx Herpes Simplex Virus 1 & 2 Kit, EraGen Biosciences,
Inc.; BD ProbeTec Herpes Simplex Viruses (HSV I & 2)
QX Amplified DNA Assays, BD Diagnostic Systems).
The IsoAmp HSV Assay uses isothermal helicase-
dependent amplification in combination with a dispos-
able, hermetically-sealed, vertical-flow strip identifica-
tion, limiting the technical hands-on time and risk of
cross-contamination. Once DNA is purified from the
sample, the assay has a total test-to-result time of about
1.5 hours. The diagnostic sensitivity and specificity are
comparable to end-point PCR and are superior to
culture-based methods. The performances have not been
compared to real-time PCR assays. The assay is FDA ap-
proved for the detection of herpes simplex viruses
(HSV) in genital and oral lesion specimens. The assay
does not provide specific typing information to differen-
tiate HSV-1 from HSV-2. The assay is not intended to
be used for prenatal screening [45].
The MultiCode-RTx Herpes Simplex Virus 1 & 2 Kit uti-
lizes real-time PCR molecular detection. MultiCode-RTx
technology site-specifically incorporates an isoG triphos-
phate, covalently attached to a DABCYL quencher, opposite
an isoC base that is adjacent to a 5 fluorescent label in one
of the primers. PCR amplification is performed using the
Roche LightCycler 1.2 instrument. Incorporation of the
quencher-labeled nucleotide causes a decrease in assay
fluorescence when the product is a double-stranded DNA
molecule. The PCR primers target a type-specific DNA se-
quence within the herpes simplex virus glycoprotein B
gene. The MultiCode-RTx Herpes Simplex Virus 1 & 2 Kit
is indicated for use in the detection and typing of HSV-1 or
HSV-2 in vaginal lesion swab specimens from symptomatic
female patients. The assay provided similar sensitivity and
specificity compare to two other commercial real-time PCR
assays on CSF samples [46].
The BD ProbeTec Herpes Simplex Viruses (HSV-1 & -2)
QX Amplified DNA Assay is a fully automated assay for
HSV-1 and HSV-2 molecular detection and typing on the
BD Viper™ System. The PCR primers target a type-specific
DNA sequence within the HSV glycoprotein G gene. It is
approved for the detection and differentiation of HSV-1
and HSV-2 in anogenital samples. It has been compared to
HSV culture and a laboratory-developed real-time PCR
assay with 508 clinical specimens. The sensitivity of HSV-2
detection ranged from 98.4-100% depending on the analyt-
ical approach, while the specificity ranged from 80.6%,
compared to the less sensitive culture method, to 97.0%,
compared to PCR. For HSV-1, the sensitivity and specificity
ranges were 96.7-100% and 95.1-99.4%, respectively [47].
Indirect serological diagnosis of herpetic infections
Detection of HSV-specific IgG antibodies can be done sen-
sitively by several immunological methods. Serologic diag-
nosis of HSV infections and HSV type-specific antibody
testing are summarized in Table 5, and commercially avail-
able assays approved by the Food and Drug Administration
(FDA, United States) in Table 6. Accurate type-specific
HSV serologic assays are based on the detection of HSV-
specific gG1 (HSV-1) and gG2 (HSV-2) antibodies using
native, purified or recombinant gG1 or gG2 as antigens.
Serological assays based on antigen preparations from
whole virus or from crude infected-cell protein mixtures
detect predominantly type-common antibodies, may have
low sensitivity in detecting HSV-2 antibodies in HSV-1
seropositive patients, or may incorrectly type antibodies in
patients with only HSV-1 or HSV-2 infection. Some com-
mercial assays described as type-specific are actually
based on relative reactivity of serum antibodies to crude
preparations of HSV-1 versus HSV-2 antigens. The accur-
acy of such tests for HSV-2 antibody detection is low com-
pared with glycoprotein Gbased tests, and their use is not
recommended [48].
Type-specific IgG antibodies are negative in early pre-
sentations of herpes disease, and become detectable two
weeks to three months after the onset of symptoms and
persist indefinitely. Thus, immediately after infection
there is a window in which testing for antibodies will
give a negative result. Consequently, primary HSV infec-
tions can be documented by using any serologic
methods to show seroconversion with paired sera. HSV
IgM testing substantially increased the ability to detect
early infection in patients who lack detectable IgG, but
may be negative during primary disease. IgM testing can
also be positive during reactivation of disease and cannot
be used to distinguish primary from recurrent infection.
Because of these limitations, HSV IgM testing has lim-
ited availability in routine diagnostic settings and cannot
be recommended in routine clinical practice.
Gold standard noncommercial tests for HSV-2 include
the immunodot enzyme assay (developed at Emory Univer-
sity, Atlanta, Georgia, United States), the Western blot test
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Table 5 Indirect serological assays for HSV diagnosis
Method Principle Sample Sensitivity Specificity Advantages Disadvantages
Western blot Western blot HSV-1 Serum ≈100% ≈100% Reference (“gold standard”) test proposed by University of Washington (USA) Not commercially
available
Expensive[UW-WB]
Specific of HSV-1 and HSV-2 2–3 days for resultsWestern blot HSV-2
Detect early sero-conversion to HSV-2 in patient with prior HSV-1 infection
Earliest sero-conversion : 13 days
Enzyme
immune-assay
Monoclonal
antibody-blocking EIA
Serum’ ≈100% ≈100% Reference (“gold standard”) test proposed by the Central Public Health Laboratory in
the United Kingdom; 98% concordance with WU-WB
Not commercially
available
(African
sera : 98%)
(African
sera : 97%) Distinguish between HSV-1 and HSV-2
Enzyme
immune-assay
ELISA Serum 93–98% 93–99% Commercially available May lack of sensitivity
and specificity
Distinguish between HSV-1 and HSV-2 Lack of specific on
African sera
Point of care
tests
Immuno-filtration Serum
Capillaryblood
96% 87–98% Less expensive than Western blot Commercially available
only for HSV-2
Accurate results rapidly (6 min.) Expensive
Not for large volume
screening
Easily to carry out
Detects seroconversion within 4 weeks of presentation of 80% of patients with HSV-2
episodes
Complexity nonwaived
(moderate)
ELISA:Enzyme-linked immunosorbent assay; EIA: Enzyme immunoassay;
UW-WB: Western blot test developed at the University of Washington.
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Table 6 Commercially available serological assays for HSV diagnosis approved by the Food and Drug Administration (US) (FDA, 2013)
HSV-1 HSV-2
Assay Manufacturer Format Collection method Sensitivity Specificity Sensitivity Specificity
Biokit HSV-2 Rapid Test Biokit Point of care Heparinized capillary
whole blood, serum
NA NA 93%-96% 95%-98%
HerpeSelect HSV-1 and HSV-2 Immunoblot Focus Diagnostics Western blot with
recombinant proteins
Serum 99.3% 95.1% 97.3% 93.7%
HerpeSelect HSV-1 ELISA, HerpeSelect HSV-2 ELISA Focus Diagnostics ELISA Serum 91.2%-96% 92. 3%-95.2% 96.1% -100% 97.0%-96.1%
CaptiaHsv 1 IgG Type Specific Elisa Kit&CaptiaHsv
2 IgG Type Specific Elisa Kit
Trinity Biotech ELISA Serum 87.9%-87.7% 100%-98.2% 96.7%-100% 90.3%-91.5%
Liaison HSV-1 & Liaison HSV-2 Type SpecificIgGAssay Diasorin ELISA Serum 96.9%-98.7% 91.3%-96.8% 98.1%-94.8% 98.0%-97.3%
Zeus ELISA HSV GG-2 IgG Test System & Zeus ELISA
HSV GG-1 IgG Test System
Zeus Scientific ELISA Serum 96.8% 97.1% 98.8% 100%
BioPlex HSV-1 & HSV-2 IgG panel Biorad Luminex Serum, lithium heparini
plasma, EDTA plasma
100%-100% 98. 3%-97.4% 99.4%-100% 100%-100%
Elecsys HSV-1 IgG and HSV-2 IgG assays Roche Diagnostics Chemiluminescence Serum, lithium heparin
plasma, EDTA plasma
94.2%-91.0% 90. 3%-95.7% 93.6%-97.8% 98.7%-98.7%
NA: Not Applicable.
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(developed at the University of Washington (UW-WB)),
and the monoclonal antibody-blocking enzyme immuno-
assay (developed by the Central Public Health Laboratory,
London, United Kingdom) [49,50]. These tests are used in
their respective specialized reference laboratories but are
not replicable in many settings, thereby limiting their suit-
ability for large-scale epidemiologic studies. The UW-WB
test has been used as a gold standard in several studies, in-
cluding the evaluation of commercial serological assays re-
quired for clearance by the FDA, and in the evaluation of
the performance of other gold standard tests. Despite its ex-
cellent performance, Western blot remains primarily a re-
search tool. At present, Western blot is not FDA approved,
and requires a high level of technical ability, time, and ex-
pense to perform.
Type-specific HSV glycoprotein G (gG)-based ELISA
became commercially available in 1999. The sensitivities
of these gG type-specific tests for the detection of HSV-
2 antibody vary from 8098%, and false-negative results
might be more frequent at early stages of infection [51].
The specificities of these assays are ≥96%. The tests ap-
proved for use in the USA have sensitivity of 97100%
and specificity of 9498%, when measured in compari-
son with the Western blot. False-positive results can
occur, especially in patients with a low likelihood of
HSV infection. Repeat or confirmatory testing might be
indicated in some settings, especially if recent acquisi-
tion of genital herpes is suspected [51]. Some HSV-2
strains have been identified with mutations or deletions
in gG2-gene leading either to the lack of gG-2 expres-
sion or the production of truncated forms [52,53]. Infec-
tions with such variants caused genital lesions similar to
wild HSV-2 infection but immune response to gG-2
were either reduced or absent [52,53]. Negative detec-
tion of type-specific HSV-2 antibodies does not elimin-
ate the rare possibility of a HSV-2 infection. HSV-2
DNA detection or HSV-2 isolation in cell culture along
with a negative serology beyond the primary infection
suggests an infection with a gG-2 deficient HSV-2 strain.
HerpeSelect® ELISA tests (HerpeSelect® 1 ELISA IgG
Herpes Simplex Virus-1 (HSV-1) ELISA IgG; HerpeSe-
lect® 2 ELISA IgG Herpes Simplex Virus-2 (HSV-2)
ELISA IgG,Focus Technologies, Inc., Cypress, CA
[formerly MRL Diagnostics]) are FDA approved, widely
available and have been extensively studied [51,54-57].
Point-of-care rapid tests can also provide results for
HSV-2 antibodies from capillary blood or serum during
a clinic visit. These immunoassays are designed to use
capillary blood from a finger stick (or serum) and typic-
ally employ lateral flow of serum through a membrane
containing a dot of gG1 or gG2 antigen. When serum is
applied to the kit, a visual color change develops (pink
dot) if herpes antibodies are present. Despite a reported
inter-operative variability of 5-10% in test interpretation,
these point-of-care tests perform relatively well with sen-
sitivities ≥91% and specificities ≥94% [48]. The major
benefit of point-of-care assays is that they give results
rapidly (potentially while the patient is still in the clinical
site,) allowing for more timely patient education and
counseling. The major drawback of these tests is their
cost relative to herpes ELISA-based systems.
If genital lesions are present, type-specific serology
and direct virus testing can help to establish if the epi-
sode is a new HSV infection or reactivation (Table 7).
Type-specific HSV antibodies can take from 2 weeks
to 3 months to develop. Thus, in a person with newly
acquired herpes the initial absence of IgG antibodies
specific for gG and subsequent development of such
antibodies after 12 weeks confirms new HSV infection.
The distinction between newly acquired HSV and
reactivated HSV is helpful for epidemiological studies,
and is sometimes helpful clinically for management of
Table 7 Virological and serological approach to HSV-2 diagnosis in the presence and absence of genital lesions,
adapted from Gupta and colleagues [5]
HSV-2 detection
by direct method
HSV-1-
specific IgG
HSV-2-
specific IgG
Interpretation
First assessment of genital
lesions
Positive Positive or
negative
Negative Acute HSV-2 infection
Repeat HSV-2-specific serology within 15-30 days
Positive Positive or
negative
Positive Recurrent HSV-2 infection with HSV-2 infection acquired at least
6 weeks ago
No lesions NA Negative Negative Patients at risk for acquiring orolabial or genital HSV-1 infection and/
or HSV-2 infections
NA Positive Negative Patients at risk for acquiring orolabial or genital HSV-2 infections
NA Positive Positive HSV-1 and HSV-2 past-infections
Recurrentgenitallesions Positive Positive or
negative
Positive Recurrent HSV-2 infection
Negative Negative Positive Possible recurrent HSV-2 infection Other potential causes of genital
ulcerative disease should be considered
NA: Not applicable.
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psychosocial issues, because it can help clarify the source
of infection.
Because nearly all HSV-2 infections are sexually ac-
quired, the presence of type-specific HSV-2 antibody
implies anogenital infection; thus, education and coun-
seling appropriate for people with genital herpes should
be provided. The presence of HSV-1 antibody alone is
more difficult to interpret. The majority of people with
HSV-1 antibody have oral HSV infection acquired dur-
ing childhood, which might be asymptomatic. However,
acquisition of genital HSV-1 appears to be increasing,
and genital HSV-1 also might be asymptomatic.
Taken together, type-specific HSV serological assays
might be useful in the following situations (Table 8):
 Recurrent genital symptoms or atypical symptoms
with negative HSV cultures;
 Clinical diagnosis of genital herpes without
laboratory confirmation;
 Partner with genital herpes.
In addition, HSV serologic testing should be included
in a comprehensive evaluation for STIs among people
with multiple sex partners, HIV infection, and men who
have sex with men who are at increased risk for HIV ac-
quisition. Screening for HSV-1 or HSV-2 in the general
population is not recommended, due to concerns that
HSV-2 diagnosis provides no benefit and could lead to
psychosocial sequelae (Table 8).
However some data suggest that most people are in-
terested in HSV-2 testing, which may result in safer sex
practice. A review examined studies that measured the
short and long-term psychosocial effects resulting from
serological diagnosis of HSV-2 in persons without recog-
nized symptoms of genital herpes infection [58]. Overall
HSV-2 serological testing did not result in long-term
psychosocial harm in most people. Recently a study con-
ducted in pregnant women showed that serotesting sex-
ual partners of pregnant women for HSV reduced the
frequency of unprotected genital sex acts in pregnant
women at known risk of HSV-2 acquisition compare to
HSV-2-seronegative women with partners who were
negative or not tested [59].
Therapeutic monitoring: drug resistance testing
Long-term prophylaxis and treatment with antiviral
drugs targeting the viral DNA polymerase (DNA pol)
can result in the development of resistance [60]. The
prevalence of acyclovir-resistant HSV is about 1% in
immunocompetent individuals and increases in immun-
compromised patients, 5% in HIV-seropositive individ-
uals and 30% in hematopoietic stem cell recipients
[61,62]. Antiviral drugs such as acyclovir or valacyclovir
inhibit the viral DNA pol in triphosphorylated form, the
first phosphorylation step ensured by the viral thymidine
kinase (TK) and the subsequent steps by host cell ki-
nases. Therefore mutations in both DNA pol and TK
may confer resistance to antiviral drugs (Table 9). Be-
cause a functional TK may be dispensable but not the
DNA pol for HSV replication, there is a higher probabil-
ity of inducing a viable acyclovir-resistant virus by a mu-
tation in the UL23 gene coding for TK than by a
mutation in the UL30 gene coding for DNA pol.
Table 8 Indications of type specific serology
Context Indication and interpretation
Asymptomatic patients Not routinely recommended
Confirmation of clinical diagnosis HSV-2 antibodies are supportive of
a diagnosis of genital herpes.
History of recurrent or atypical
genital disease with direct virus
detection negative
HSV-1 antibodies do not
differentiate between genital and
oropharyngeal infection.
Counseling of HSV-2 IgG-negative,
HSV-1 IgG-positive patients should
take into account that HSV-1 is an
uncommon cause of recurrent
genital disease.
First-episode genital herpes Differentiation between primary
and established infection guides
counseling and management.
At the onset of symptoms, the
absence of HSV IgG against the
virus type detected in the genital
lesion is consistent with a primary
infection.
Seroconversion should be
demonstrated at follow-up.
Partner with genital herpes Knowledge of infection status can
guide patient education and
counseling if the partnership is
discordant.
Pregnant women Not routinely recommended.
HSV-1 and/or HSV-2 seronegative
women should be counseled
about strategies to prevent a new
infection with either virus type dur-
ing pregnancy.
HIV infected patients Not routinely recommended.
Although HSV-2 seropositivity in-
creases the risk of HIV transmission
and frequent HSV recurrences aug-
ment HIV replication, there is lim-
ited evidence to inform the
management of HSV-2 co-infection
in HIV-infected patients without
symptoms of genital herpes.
Limited data suggest an increased
risk of perinatal HIV transmission
among HSV-2 seropositive HIV-
infected women. As the evidence
is not consistent, testing of HIV-
positive pregnant women is not
routinely recommended.
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Table 9 Molecular changes associated with anti-herpetic drugs resistance in thymidine kinase (TK) and DNA polymerase (DNA pol) genes of Herpes simplex
virus type 1 (HSV-1) and type 2 (HSV-2) according to amino acid mutations, stop codon and nucleotide insertion or deletion reported in the literature [29-34]
Gene Drug Aminoacidmutationsa Stop codona Nucleotide insertion/deletionb Association of mutationsa
HSV-1 TK ACV R51W, Y53P/D/H, D55N, G56S/V, P57H, K62N, H58R/L,
G59R/Y/W, G61V, K62N, T63A/I/S, T64A/S, T65N, E83K,
P84S, V87H, T103P, Q104H, H105P, Q125E/L, M128A/F,
G129D, G144N/R, A156V, D162A, R163H/C, A167V,
A168T, L170P, Y172C/F, P173L/R, A174P, A175V, R176Q,
L178R, S181N, Q185R, V187M, A189V, G200C/D, T201P,
G206R, L208H, R216C/H/S, R220C/H, R222C/H, L227F,
Y239S, T245M/P, T287M, L297S, L315S, C336Y, L364P
Y53, S74, E95, T103, Q104,
R176, Q250, Q261, R281,
L341, C336, Q342, L364,
A375
133-136, 153-155, 180-183, 184-187
430-436, 437-438,455-458, 460-464,
464-465, 548-553,615-619, 666-669,
853-856, 878-880, 896-900, 1061-1064
HSV-2 TK ACV R34C, R51W, G56E, G59P, P85S, N100H, Q105P, T131P,
R177W, S182D, S182N, V192M, T202A, R217H, R221H,
R221C, R223H, L228I,D229H, R272V, P273S, D274R,
T288M,C337Y
A28, L69, D137, Q222,
Y240, T264
215-217, 219-222222, 439-440, 452,
467, 519-521, 551-556, 586-591,
626-628, 808-812
R272V + P273S + D74R
P85S + N100H + V192M
HSV-1 DNA pol ACV D368A, E370A, V462A, K532T, Y557S, Q570R, D581A,
G597K/D, A605V, Q618H, Y696H, R700G, L702H, V714M,
V715M, F716L, A719V/T, S724N,E771Q, L774F, L778M,
D780N, L782I, P797T, E798K, L802F, V183M,
N815L/S/T/V/Y/E, Y818C, T821M, G841S/C, R842S,
S889A, F891C/Y, V892S, D907V, I922N/T, Y941H, V958L,
R959H, N961K, D1070N
A719V + V904M
A327T + A605V
T566A + A605V
FCV N494S, A605V, F716L, A719V,A719T, S724N, L778M,
D780N, L782I, E798K, F891C, D907V, V958L
A719V + V904M
A327T + A605V
S724N + A916V
CDV A136T, R700H, R700M, S724N, T821M, L1007H, I1028T
ACV + FCV A605V, F716L, A719V, A719T, S724N, L778M, D780N,
L782I, E798K, F891C, D907V, V958L
A719V + V904M
A327T + A605V
ACV + CDV T821M
HSV-2 DNA pol ACV E250Q, R628C, E678G, A724V, S725G, D785N, D912N/V
FCV S725G, S729N, L783M, D912V
ACV + FCV S725G, D912V
aThe number is the amino acid position in the protein. The two letters correspond respectively to the wild type amino acid and the mutated amino acid.
bNucleotide numbering TK: thymidine kinase, DNA pol: DNA polymerase, ACV: aciclovir, FCV: foscarnet, CDV: cidofovir.
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Accordingly, 95% of clinical isolates exhibiting acyclovir
resistance harbor mutations in UL23 gene [61,62].
Resistance may be suspected when lesions persist for
more than 1 week after initiating antiviral treatment or
the emergence of new satellite lesions during treatment.
A virological confirmation helps health care profes-
sionals choose among different treatment options while
it avoids the selection of multidrug-resistant strains [63].
Resistance can be assessed by the detection of specific
mutations in UL23 or UL30 genes conferring resistance
to antiviral drugs (genotypic assays) or by testing a virus
against antiviral agents (phenotypic assays). Because
most resistance cases are due to TK deficiency or to de-
fective TK activity, mutations in the UL23 gene should
be tested first. Genotypic assays consist of the compari-
son of UL23 and UL30 genes sequences with the whole
panel of mutations described in the literature (Table 9)
[61-67]. To be useful in clinical practice, it is essential to
be able to discriminate between random variations (poly-
morphism) and true drug resistance mutations. There-
fore, when possible, it is best to test in parallel strains
collected before and on antiviral therapy. Before starting
genotypic assays, an estimation of the viral load should
be obtained because the amplification may be hampered
at low levels, especially for the UL30 gene that has been
shown to need more than 4.5 and 5.5 log10 copies/ml
for HSV-1 and HSV-2 respectively. Virus isolation in cell
culture may be required to increase the input of DNA
material [64]. However amplification in cell culture can
alter the population balance in the native sample.
Phenotypic assays are based on the measurement of
virus growth inhibition in the presence of antiviral drugs.
Various concentrations of virus are incubated with vari-
ous concentrations of antiviral drugs, and the determin-
ation of the reduction of virus-induced cytopathic effect
or plaque formation compared to a reference strain or
the strain isolated before treatment enables the measure-
ment of viral susceptibility to antiviral drugs. The gold
standard phenotypic method for the evaluation of HSV
susceptibility is the plaque reduction assay [60,62].
Although TK is not essential for growth in cell culture,
it is important for viral pathogenesis, particularly for re-
activation from latently infected trigeminal ganglia in
animal models [68,69]. This feature has likely minimized
the development of TK based resistance in the immuno-
competent community. In patients with ACV resistant
strain, cessation of antiviral treatment results in rever-
sion of HSV isolates to ACV sensitivity [70]. The most
frequent strains reactivated after an episode caused by a
resistant HSV strain are thus ACV-sensitive [70]. How-
ever reactivation of some TK-negative HSV clinical iso-
lates have been reported [71,72]. Therefore, despite an
initial antiviral efficacy, the same resistance will likely be
selected as the previous episode and ACV treatment
may fail, especially if the immunosuppression condition
remained.
Conclusion
Laboratory confirmation of clinically suspected genital
herpes diagnosis is necessary. In addition to helping the
therapeutic management of ulcerative genital lesions and
herpes diagnosis, it helps identify persons at risk of
transmitting infection. Direct diagnosis is recommended
and validated molecular assays are a good alternative to
cell culture. Indirect diagnosis should use only FDA or
CE approved type-specific serology based on glycopro-
tein G1 and G2 antigens and has to be considered for
recurrent genital symptoms or atypical symptoms with-
out laboratory confirmation and for testing pregnant
women at risk of acquiring HSV infection.
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